

**Commercial/Healthcare Exchange PA Criteria**  
*Effective: November 7<sup>th</sup>, 2018*

**Prior Authorization:** Orilissa

**Products Affected:** Orilissa (elagolix) oral tablet

**Medication Description:**

Orilissa is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis.

Orilissa binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and causes a dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately resulting in decreased serum concentrations of estradiol and progesterone.

**Covered Uses:** For the management of moderate to severe pain associated with endometriosis

**Exclusion Criteria:**

1. Pregnancy
2. Osteoporosis
3. Severe hepatic impairment (Child Pugh C)

**Required Medical Information:**

1. Diagnosis
2. Dose and frequency
3. Child Pugh score
4. Chart notes documenting the absence of osteoporosis
5. Current and previous medical history (documentation required)

**Age Restrictions:** 18 years of age or older

**Prescriber Restrictions:** Prescribed by, or in consultation with, an obstetrics/gynecology or reproductive specialist.

**Coverage Duration:**

- Initial: 6 months
- Renewal (150 MG): 18 months, maximum of 24 months
- Renewal (200 MG): No renewal

**Other Criteria:**

*Initial:*

Approve if the patient meets the following criteria (A, B, C, D, E, AND F):

- A. Patient has a diagnosis of moderate to severe pain associated with endometriosis; **AND**
- B. Patient is 18 years of age or older; **AND**
- C. Orilissa is prescribed by, or in consultation with, an obstetrics/gynecology or reproductive specialist; **AND**
- D. Patient is not pregnant; **AND**
- E. Patient does not have osteoporosis; **AND**
- F. Patient does not have severe hepatic impairment (Child Pugh C).

*Continuation:*

Approve if the patient meets the following criteria (A AND B):

- A. Patient continues to meet initial criteria above; AND
- B. Patient is not currently taking 200mg; AND
- C. Patient has not been taking 150mg for greater than 24 months.

**References:**

- 1. Orilissa [package insert]. North Chicago, IL; Abbvie. July 2018.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	11/7/2018